Vanguard Group Inc. Increases Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Vanguard Group Inc. grew its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 2.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,824,212 shares of the company’s stock after buying an additional 68,151 shares during the quarter. Vanguard Group Inc. owned 0.05% of Zevra Therapeutics worth $23,554,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. bought a new stake in shares of Zevra Therapeutics in the 4th quarter worth approximately $94,000. XTX Topco Ltd bought a new position in shares of Zevra Therapeutics during the third quarter worth $94,000. Virtu Financial LLC bought a new stake in shares of Zevra Therapeutics in the 3rd quarter worth about $127,000. SG Americas Securities LLC lifted its stake in Zevra Therapeutics by 54.6% in the fourth quarter. SG Americas Securities LLC now owns 23,500 shares of the company’s stock worth $196,000 after purchasing an additional 8,302 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in Zevra Therapeutics in the fourth quarter worth approximately $224,000. Institutional investors own 35.03% of the company’s stock.

Analyst Ratings Changes

ZVRA has been the subject of a number of recent analyst reports. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group increased their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, March 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Thursday, March 13th. Finally, Guggenheim increased their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zevra Therapeutics currently has an average rating of “Buy” and an average target price of $22.29.

Zevra Therapeutics Stock Down 0.3 %

Zevra Therapeutics stock opened at $6.96 on Wednesday. The firm’s 50 day moving average price is $7.63 and its two-hundred day moving average price is $8.14. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. Zevra Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $9.76. The firm has a market cap of $376.65 million, a PE ratio of -3.53 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The business had revenue of $12.00 million for the quarter, compared to analyst estimates of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. On average, research analysts predict that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Insider Activity

In other Zevra Therapeutics news, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the transaction, the chief financial officer now directly owns 51,361 shares in the company, valued at approximately $403,697.46. The trade was a 17.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Joshua Schafer sold 10,500 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $82,530.00. Following the completion of the sale, the executive vice president now directly owns 29,486 shares in the company, valued at $231,759.96. This represents a 26.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 85,773 shares of company stock valued at $674,176 over the last three months. 2.40% of the stock is owned by insiders.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.